While brain tumors treated with anti-GITR (2a) did not have significantly lower levels of intratumoral CD4 + FoxP3+ cells relative to control, anti-GITR (2a) treatment in flank tumors did result in a significantly diminished proportion of CD4 + FoxP3+ relative to control (Fig. 5e, f). This evidence concerns the gene CD4 and brain neoplasm.